BNTX BioNTech SE — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$88.08

Period return

-9.20 (-9.46%)

Volume

837.2K

2026-06-05O $89.51 H $89.95 L $87.75 C $88.08MA5 $89.39MA20 $91.33MA60 $94MA120 $99

6M · 124 barsYahoo Finance · USD2025-12-08 → 2026-06-05

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 05. 28.MediumBUY10 days ago
UBS: Buy
US analyst rating / recommendation change.
2026. 05. 22.MediumHOLD15 days ago
Bernstein: Market Perform
US analyst rating / recommendation change.
2026. 05. 07.LowBUYlast month
Canaccord Genuity: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $124.36 · 19 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.

2026. 05. 06.LowBUYlast month

Wells Fargo: Overweight